Ticker League

EPS (Diluted) for Regeneron Pharmaceuticals (REGN)

Latest filings through · Reported

Metric

TTM

$41.04

YoY change

+8.2%

5Y CAGR

+6.3%

Peak year (2021)

$71.97

EPS (Diluted) history chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025

Latest: $41.48

EPS (Diluted) growth chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025

Latest: +8.2%

EPS (Diluted) history table for Regeneron Pharmaceuticals (REGN) from 1990 to 2025

  • 2025$41.48+8.2%
  • 2024$38.34+10.3%
  • 2023$34.77-9.0%
  • 2022$38.22-46.9%
  • 2021$71.97+135.8%
  • 2020$30.52+65.3%
  • 2019$18.46-13.3%
  • 2018$21.29+105.9%
  • 2017$10.34+34.3%
  • 2016$7.70+39.5%
  • 2015$5.52+85.2%
  • 2014$2.98-19.9%
  • 2013$3.72-44.9%
  • 2012$6.75-375.5%
  • 2011−$2.45+94.4%
  • 2010−$1.26+48.2%
  • 2009−$0.85-19.0%
  • 2008−$1.05-34.0%
  • 2007−$1.59-10.2%
  • 2006−$1.77+3.5%
  • 2005−$1.71-331.1%
  • 2004$0.74-134.7%
  • 2003−$2.13-24.7%
  • 2002−$2.83+56.4%
  • 2001−$1.81+174.2%
  • 2000−$0.66-9.6%
  • 1999−$0.73+160.7%
  • 1998−$0.28-30.0%
  • 1997−$0.40-69.7%
  • 1996−$1.32+10.9%
  • 1995−$1.19-26.5%
  • 1994−$1.62-32.8%
  • 1993−$2.41+94.4%
  • 1992−$1.24+327.6%
  • 1991−$0.29+38.1%
  • 1990−$0.21—

EPS (Diluted) values are taken from Regeneron Pharmaceuticals's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About EPS (Diluted) at Regeneron Pharmaceuticals (REGN)

According to Regeneron Pharmaceuticals's latest reported financial statements, the company's current diluted EPS (TTM) is $41.04. Diluted earnings per share (EPS) is net income divided by the diluted weighted-average shares outstanding over the period. It expresses profit on a per-share basis — the figure investors use to value an individual share — and accounts for potential dilution from options, RSUs, and convertible securities.

Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .

As of the 2025 fiscal year, Regeneron Pharmaceuticals (REGN) reported diluted EPS of $41.48 – grew 8.2% year-over-year.

Through 2020–2025 (5 years), Regeneron Pharmaceuticals diluted EPS delivered a +6.3% annualised rate; sustaining 2 straight years of year-over-year growth.

Between 2021 and 2025, Regeneron Pharmaceuticals diluted EPS plunged 42.4%, falling from $71.97 to $41.48.

$71.97 stands as the all-time-high annual diluted EPS, posted in 2021, against a low of −$2.83 during 2002.

Regeneron Pharmaceuticals EPS (Diluted) by Year

Regeneron Pharmaceuticals EPS (Diluted) 2025: $41.48

Regeneron Pharmaceuticals diluted EPS in 2025 was $41.48, grew 8.2% from 2024.

Regeneron Pharmaceuticals EPS (Diluted) 2024: $38.34

2024's diluted EPS for Regeneron Pharmaceuticals came in at $38.34, grew 10.3% from 2023.

Regeneron Pharmaceuticals EPS (Diluted) 2023: $34.77

Regeneron Pharmaceuticals posted diluted EPS of $34.77 in 2023, declined 9.0% below 2022.

Regeneron Pharmaceuticals EPS (Diluted) 2022: $38.22

In 2022, Regeneron Pharmaceuticals reported diluted EPS of $38.22, plunged 46.9% below 2021.

Regeneron Pharmaceuticals EPS (Diluted) 2021: $71.97

Regeneron Pharmaceuticals diluted EPS in 2021 was $71.97.

See more financial history for Regeneron Pharmaceuticals (REGN). Or calculate EPS yourself.

Sector peers by EPS (Diluted)

Healthcare peers of Regeneron Pharmaceuticals (REGN), ranked by their latest diluted EPS

Frequently asked questions

Regeneron Pharmaceuticals (REGN) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation